ArticleJournal of biochemical and molecular toxicology2026
Modulatory Role of Melatonin in Cyclophosphamide-Treated Platelets: Insights From Ex Vivo Oxidative Stress Model.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclophosphamide (CYP) is implicated in oxidative stress (OS)-related platelet destruction during chemotherapy, leading to thrombocytopenia. Antioxidants can potentially attenuate the side effects of drugs and improve therapeutic outcomes. Melatonin is highly permeable and has radical scavenging and antioxidant enzyme-stimulating activity. This study investigates the influence of melatonin on platelets during CYP-induced OS under ex vivo conditions. Platelets isolated from the whole blood of male Wistar rats (n = 5) were categorized and treated as follows: Controls (CON) and Experimentals: (i) CYP, (ii) melatonin (MEL), and (iii) CYP+melatonin (CYP + MEL). Antioxidant defenses, OS and platelet function markers were assessed. Catalase, total antioxidant capacity (TAC), and lactate dehydrogenase decreased; ATP secretion, activation and cell viability decreased; and glucose and aggregation increased in CYP compared to CON. Catalase, TAC and glucose were maintained in MEL compared to CON. However, catalase increased, thereby decreasing lipid peroxidation and enhancing activation and aggregation in CYP + MEL compared to CYP. Melatonin mitigates CYP-induced cellular damage by scavenging ROS and augmenting antioxidant defenses. Platelets possess a complex network of signaling cascades, and can serve as ex vivo models to study platelet dysfunction. They can provide insights into platelet behavior under simulated physiological and pathological conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.